Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced that Chief Executive Officer Amir Reichman will co-lead a Manufacturers Association of Israel-organized roundtable discussion during HealthIL Week 2026. The session, titled "Biopharma Manufacturing in Israel: Capabilities, Gaps, and Scale," is scheduled for January 19, 2026, at Expo Tel Aviv and will focus on Israel's biopharma development and manufacturing ecosystem.
The roundtable discussion will examine early-stage development, chemistry, manufacturing, and controls (CMC) activities, and clinical manufacturing, as well as readiness for later-stage and commercial manufacturing. This comprehensive examination comes at a critical time as Israel seeks to strengthen its position in the global biopharmaceutical market. The session is expected to bring together representatives from government agencies, biopharma manufacturers, contract development and manufacturing organizations (CDMOs), multinational pharmaceutical companies, biotech firms, and investors to examine current capabilities, structural gaps, and collaboration models shaping the sector's future.
The importance of this discussion extends beyond Scinai's participation, representing a significant opportunity to assess Israel's biopharmaceutical infrastructure at a pivotal moment. Israel has emerged as a hub for biotechnology innovation, but questions remain about its manufacturing capacity to support companies from early development through commercialization. The roundtable's findings could influence investment decisions, government policy, and international partnerships that determine whether Israeli biotech innovations can be manufactured at scale within the country.
Scinai Immunotherapeutics operates through two complementary business units that position the company at the intersection of this discussion. Scinai Bioservices serves as a boutique CDMO providing analytical method development, process development, and clinical cGMP manufacturing services for biotech clients worldwide. Meanwhile, Scinai R&D focuses on developing innovative inflammation and immunology therapeutics based on NanoAbs (VHH antibody fragments) with unique physicochemical properties suitable for advanced mono- and multi-specific antibody formats.
The company's dual role as both a developer of novel therapeutics and a provider of manufacturing services gives CEO Reichman unique insight into the challenges facing Israel's biopharma sector. His participation in the roundtable reflects Scinai's commitment to addressing systemic issues that affect not only the company but the entire Israeli biotech ecosystem. The discussion outcomes could have significant implications for how Israeli biotech companies approach manufacturing strategy, potentially influencing decisions about whether to build domestic manufacturing capacity or partner with international CDMOs.
For investors and industry observers, this roundtable represents an important barometer of Israel's biopharmaceutical manufacturing readiness. As detailed in the company's newsroom at https://ibn.fm/SCNI, Scinai continues to position itself at the forefront of Israel's biotech sector. The HealthIL Week 2026 event, where the full press release can be viewed at https://ibn.fm/dfb1F, will provide critical insights into whether Israel can develop the manufacturing infrastructure necessary to compete globally in biopharmaceutical production.
